Skip to main content
. 2023 Jan 27;23:95. doi: 10.1186/s12885-023-10548-4

Table 3.

Clinical characteristics of patients with primary cervical lymphoma of DLBCL subtype (N = 113)

Clinical characteristics Number (Percentile)
Age (Mean/Median, y) 49.5 ± 16.3/49.0 (20–85)
Time of follow-up (Mean/Median, y) 4.7/3.0 (0.08–20.50)
Elevated LDH (N = 20) 12 (60%)
Ann Arbor Stage
 IE 73 (64.6%)
 IIE 25 (22.1%)
 IIIE 4 (3.5%)
 IVE 11 (9.7%)
Cancer-directed surgery (CDS) 31 (27.4%)
Chemotherapy/Radiotherapy details
 No chemotherapy or radiotherapy 6 (5.3%)
 Chemotherapy alone 57 (50.4%)
  CHOP 17
  CHOP + CDS 9
  R-CHOP 13
  R-CHOP + CDS 7
 Radiotherapy alone 13 (11.5%)
 Radiotherapy + chemotherapy 37 (32.7%)
  Radiotherapy + CHOP 16
  Radiotherapy + CHOP + CDS 1
  Radiotherapy + R-CHOP 13
  Radiotherapy + R-CHOP + CDS 1
Clinical outcomes
 No evidence of disease 93 (82.3%)
 Alive with disease 6 (5.3%)
 Die of the disease 11 (9.7%)
 Die of the other disease 3 (2.7%)

Abbreviations: LDH lactate dehydrogenase, DLBCL diffuse large B-cell lymphoma, (R)-CHOP (Rituximab)-cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone